Table 2.
Antiproliferative activity of CCT068127 and seliciclib in human colon cancer and melanoma cell lines. GI50 values for cell proliferation were determined in human colon cancer and melanoma cell lines following exposure for four population doublings using SRB analysis as the endpoint (Whittaker et al., 2004). Values reported are the mean of three independent repeats ± SE. ND, not determined
| Cell line | Tissue | CCT068127 GI50 (μmol·L−1) ± SE | Seliciclib GI50 (μmol·L−1) ± SE |
|---|---|---|---|
| HT29 | Colorectal adenocarcinoma | 0.85 ± 0.03 | 15 ± 3.4 |
| HCT116 | Colon carcinoma | 0.25 ± 0.03 | 6.4 ± 1.8 |
| COLO205 | Colon adenocarcinoma | 0.50 ± 0.09 | 11 ± 1.2 |
| RKO | Colon carcinoma | 0.66 ± 0.03 | 10 ± 0.26 |
| SKMEL28 | Malignant melanoma | 0.31 ± 0.07 | 8.5 ± 2.1 |
| WM266.4 | Malignant melanoma | 0.40 ± 0.06 | 18 ± 2.4 |
| Average | – | 0.5 | 12 |